S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apyx Medical Co. stock logo
APYX
Apyx Medical
$1.38
+4.5%
$1.82
$1.21
$7.97
$47.80M1.09148,261 shs66,774 shs
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
$24.04
$24.02
$8.42
$24.25
$1.76B3.022.70 million shsN/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$7.36
-1.5%
$8.90
$3.78
$13.62
$406.42M1.67184,490 shs147,946 shs
RenovaCare, Inc. stock logo
RCAR
RenovaCare
$0.00
$0.00
$0.30
$10K12,431 shsN/A
The Westaim Co. stock logo
WEDXF
Westaim
$2.67
-0.4%
$2.66
$2.13
$2.99
$344.35M0.4630,576 shs6,571 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apyx Medical Co. stock logo
APYX
Apyx Medical
-5.04%-7.04%-25.42%-33.67%-56.00%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
0.00%0.00%0.00%0.00%0.00%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-3.98%+0.81%-23.78%-12.01%+25.13%
RenovaCare, Inc. stock logo
RCAR
RenovaCare
0.00%0.00%0.00%0.00%-99.85%
The Westaim Co. stock logo
WEDXF
Westaim
+2.29%+4.69%-0.37%-1.11%+21.27%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apyx Medical Co. stock logo
APYX
Apyx Medical
4.0763 of 5 stars
3.54.00.04.21.81.70.6
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apyx Medical Co. stock logo
APYX
Apyx Medical
3.00
Buy$6.17346.86% Upside
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/A
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apyx Medical Co. stock logo
APYX
Apyx Medical
$52.35M0.91N/AN/A$0.78 per share1.77
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
$88.02M19.96N/AN/A$0.21 per share114.48
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$700K580.60N/AN/A$0.81 per share9.09
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
$8.63M39.90$1.43 per share1.87$3.95 per share0.68

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$18.71M-$0.54N/AN/AN/A-35.75%-54.90%-28.41%5/9/2024 (Estimated)
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
-$47.35M-$0.82N/AN/AN/A-16.95%-39.36%-13.02%N/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-$42.21M-$0.89N/AN/AN/A-112.74%-61.09%5/9/2024 (Estimated)
RenovaCare, Inc. stock logo
RCAR
RenovaCare
-$4.47MN/A0.00N/AN/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
$183.98M$1.302.05N/A2,132.63%37.84%34.98%5/14/2024 (Estimated)

Latest PLSE, WEDXF, RCAR, GNMK, and APYX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$0.13-$0.19-$0.06-$0.10$14.40 million$14.66 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apyx Medical Co. stock logo
APYX
Apyx Medical
N/AN/AN/AN/AN/A
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/AN/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apyx Medical Co. stock logo
APYX
Apyx Medical
1.23
5.52
4.74
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
0.75
4.33
3.84
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A
6.76
6.76
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/A
4.23
4.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
55.33%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
96.94%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
76.95%
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/A
The Westaim Co. stock logo
WEDXF
Westaim
N/A

Insider Ownership

CompanyInsider Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
13.10%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
3.25%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
69.70%
RenovaCare, Inc. stock logo
RCAR
RenovaCare
0.86%
The Westaim Co. stock logo
WEDXF
Westaim
4.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Apyx Medical Co. stock logo
APYX
Apyx Medical
25234.64 million30.11 millionOptionable
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
61873.09 millionN/AOptionable
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
6155.22 million16.73 millionOptionable
RenovaCare, Inc. stock logo
RCAR
RenovaCare
187.35 million86.60 millionNot Optionable
The Westaim Co. stock logo
WEDXF
Westaim
7128.97 million123.54 millionNot Optionable

PLSE, WEDXF, RCAR, GNMK, and APYX Headlines

SourceHeadline
Analyzing GlucoTrack (NASDAQ:GCTK) & Westaim (OTCMKTS:WEDXF)Analyzing GlucoTrack (NASDAQ:GCTK) & Westaim (OTCMKTS:WEDXF)
americanbankingnews.com - April 8 at 1:17 AM
The Westaim Corporation Reports Q4 and Full Year 2023 ResultsThe Westaim Corporation Reports Q4 and Full Year 2023 Results
businesswire.com - March 27 at 4:25 PM
The Westaim Corporation Recognized on the TSX Venture 50 ListThe Westaim Corporation Recognized on the TSX Venture 50 List
businesswire.com - February 21 at 8:28 AM
Westaim Corp.Westaim Corp.
wsj.com - February 17 at 2:53 PM
DCK ELEVATES BILL BROWN TO PRESIDENTDCK ELEVATES BILL BROWN TO PRESIDENT
finance.yahoo.com - January 17 at 12:21 PM
Westaim (WEDXF) Price Target Increased by 6.07% to 3.93Westaim (WEDXF) Price Target Increased by 6.07% to 3.93
msn.com - November 27 at 5:22 PM
The Westaim GAAP EPS of $0.16The Westaim GAAP EPS of $0.16
seekingalpha.com - November 15 at 12:57 PM
The Westaim Corporation Reports Q3 2023 ResultsThe Westaim Corporation Reports Q3 2023 Results
finance.yahoo.com - November 14 at 4:56 PM
The Westaim GAAP EPS of $0.22, revenue of $35.9MThe Westaim GAAP EPS of $0.22, revenue of $35.9M
seekingalpha.com - August 15 at 9:22 PM
Westaim (WEDXF) Price Target Increased by 15.87% to 3.88Westaim (WEDXF) Price Target Increased by 15.87% to 3.88
msn.com - August 1 at 6:00 PM
Closing Bell: The Westaim Corp flat on Friday (WED)Closing Bell: The Westaim Corp flat on Friday (WED)
theglobeandmail.com - June 24 at 2:58 AM
Westaim Announces Pricing of Secondary Offering of Skyward Specialtys Common StockWestaim Announces Pricing of Secondary Offering of Skyward Specialty's Common Stock
technews.tmcnet.com - June 8 at 1:16 AM
Skyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shrSkyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shr
markets.businessinsider.com - June 8 at 1:16 AM
Westaim Announces Director ResignationWestaim Announces Director Resignation
technews.tmcnet.com - April 25 at 8:25 AM
Closing Bell: The Westaim Corp flat on Monday (WED)Closing Bell: The Westaim Corp flat on Monday (WED)
theglobeandmail.com - April 17 at 8:08 PM
The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50
technews.tmcnet.com - February 21 at 9:55 AM
Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)
nz.finance.yahoo.com - November 13 at 4:45 PM
WEDXF The Westaim CorporationWEDXF The Westaim Corporation
seekingalpha.com - October 1 at 5:43 PM
Is Westaim Corp (WEDXF) Stock a Good Investment?Is Westaim Corp (WEDXF) Stock a Good Investment?
aaii.com - September 6 at 10:24 AM
WEDXF.PK - Westaim Corp | Stock Price & Latest News | ReutersWEDXF.PK - Westaim Corp | Stock Price & Latest News | Reuters
reuters.com - September 3 at 9:42 PM
The Westaim Corporation Reports Q2 2022 ResultsThe Westaim Corporation Reports Q2 2022 Results
apnews.com - August 11 at 3:35 PM
The Westaim Corporation Reports Q1 2022 ResultsThe Westaim Corporation Reports Q1 2022 Results
finance.yahoo.com - May 17 at 11:18 AM
The Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor DayThe Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor Day
finance.yahoo.com - May 3 at 6:13 PM
Westaim earnings preview: what Wall Street is expectingWestaim earnings preview: what Wall Street is expecting
markets.businessinsider.com - April 14 at 10:42 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Apyx Medical logo

Apyx Medical

NASDAQ:APYX
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
GenMark Diagnostics logo

GenMark Diagnostics

NASDAQ:GNMK
GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company also offers Blood Culture Identification Gram-Positive and Negative panel, Blood Culture Identification Fungal Pathogen panel, and ePlex Gastrointestinal Pathogen Panel. In addition, it provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. Further, the company offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, thrombophilia risk test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test and eSensor SARS-CoV-2 Test. GenMark Diagnostics, Inc. sells its products through direct sales and technically specialized service organization in the United States, Europe, and internationally. The company was incorporated in 2010 and is headquartered in Carlsbad, California.
Pulse Biosciences logo

Pulse Biosciences

NASDAQ:PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
RenovaCare logo

RenovaCare

OTCMKTS:RCAR
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.
Westaim logo

Westaim

OTCMKTS:WEDXF
The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.